Pharmaceutical competition: Eli Lilly vs. Novo Nordisk

What happened: Eli Lilly recently won approval for a new weight loss drug, Mounjaro, solidifying its lead in the U.S. GLP-1 market. This drug showed remarkable results in clinical trials, with participants losing an average of 22.5% of their body weight. Meanwhile, Novo Nordisk, Lilly's main competitor, has also seen success with its GLP-1 drug, Ozempic, but Lilly's new product is considered more effective.

Market impact: The GLP-1 market, valued at over $20 billion, is now dominated by Eli Lilly. This competition drives demand for more effective weight loss solutions, benefiting both companies. However, Lilly's recent success could pressure Novo Nordisk to innovate faster to maintain market share. Investors are bullish on Lilly, with some analysts predicting a Nvidia-style run, while others argue Novo Nordisk is still a better buy due to its global presence and pipeline.

What to watch next: On May 18, Eli Lilly reports its Q1 earnings, which will provide insights into Mounjaro's commercial launch. On June 28, the FDA is set to decide on Lilly's semaglutide for chronic weight management, a potential game-changer if approved. Lastly, watch for clinical trial results from both companies' pipeline drugs, as competition in this space is fierce and continuous innovation is key.